Objective
The basic concept of our proposal is to develop nanoparticle-based encapsulated libraries of different immunotherapeutic biomolecules for treatment after surgery as part of a novel cancer management strategy. The current state-of-art for the management of cancer starts with surgery, after identification of an accessible tumour mass. Surgery remains an effective treatment option for many types of cancer today and it is considered curative treatment for most solid tumours. It forms part of a multidisciplinary approach used in conjunction with radiotherapy or chemotherapy. These approaches, however, have several limitations, including inability of surgical resection to affect distal metastatic disease, toxicity to healthy tissues with chemotherapy and lack of effectiveness of radiation therapy in more aggressive tumours. The observation that cancer can relapse months or years after initial surgery implies that micrometastases still resides within the body in a latent state. Our proposal is to take cancer therapy to beyond state-of-art by implementing techniques which will take us into new directions. This includes a) new methods to identify immune gene profiles and biomarkers b) transgenic mouse models where the complex interactions that underlie immune function can be visualised as multiplexed events in real time and c) the use of nanoparticle-based libraries of immune modulating reagent combinations. There are three key objectives within this project: i) to use immune gene signatures to monitor disease progression and therapeutic efficacy of immunotherapy combinations on nanoparticle-based platforms, ii) to optimise the platform to encapsulate libraries of immune components for more personalised, accurate and timely delivery of the payload to its intended target and iii) to optimise the overall cancer management process of image-guided surgery followed by postoperative immunotherapy so that we can ultimately provide a lifetime of protection against cancer.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
- medical and health sciences clinical medicine surgery
- medical and health sciences basic medicine pharmacology and pharmacy pharmaceutical drugs vaccines
- medical and health sciences clinical medicine oncology
- medical and health sciences health sciences personalized medicine
- medical and health sciences basic medicine immunology immunotherapy
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.1.3.1. - Fostering new skills by means of excellent initial training of researchers
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
MSCA-ITN-ETN - European Training Networks
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-MSCA-ITN-2015
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
2573 HT 's-Gravenhage (Den Haag)
Netherlands
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.